Direct-acting antivirals for chronic hepatitis C

• Published in: Cochrane database of systematic reviews 2017-06, Vol.6 (6), p.CD012143
• Main Authors: Jakobsen, Janus C, Nielsen, Emil Eik, Feinberg, Joshua, Katakam, Kiran Kumar, Fobian, Kristina, Hauser, Goran, Poropat, Goran, Djurisic, Snezana, Weiss, Karl Heinz, Bjelakovic, Milica, Bjelakovic, Goran, Klingenberg, Sarah Louise, Liu, Jian Ping, Nikolova, Dimitrinka, Koretz, Ronald L, Gluud, Christian
• Format: Article
• Language: English
• Subjects: Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Cause of Death; Hepacivirus - drug effects; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - mortality; Humans; Medicine General & Introductory Medical Sciences; Nucleic Acid Synthesis Inhibitors - adverse effects; Nucleic Acid Synthesis Inhibitors - therapeutic use; Placebos - therapeutic use; Protease Inhibitors - adverse effects; Protease Inhibitors - therapeutic use; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Simeprevir - adverse effects; Simeprevir - therapeutic use
• ISSN: 1469-493X; 1469-493X
• DOI: 10.1002/14651858.CD012143.pub2

Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). However, it is still questionable if eradication of hepatitis C virus in the blood eliminates hepatitis C in the body, and improves survival and leads to fewer complications. To assess the benefits and harms of DAAs in people with chronic HCV. We searched for all published and unpublished trials in The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, LILACS, and BIOSIS; the Chinese Biomedical Literature Database (CBM), China Network Knowledge Information (CNKI), the Chinese Science Journal Database (VIP), Google Scholar, The Turning Research into Practice (TRIP) Database, ClinicalTrials.gov, European Medicines Agency (EMA) (www.ema.europa.eu/ema/), WHO International Clinical Trials Registry Platform (www.who.int/ictrp), the Food and Drug Administration (FDA) (www.fda.gov), and pharmaceutical company sources for ongoing or unpublished trials. Searches were last run in October 2016. Randomised clinical trials comparing DAAs versus no intervention or placebo, alone or with co-interventions, in adults with chronic HCV. We included trials irrespective of publication type, publication status, and language. We used standard methodological procedures expected by Cochrane. Our primary outcomes were hepatitis C-related morbidity, serious adverse events, and quality of life. Our secondary outcomes were all-cause mortality, ascites, variceal bleeding, hepato-renal syndrome, hepatic encephalopathy, hepatocellular carcinoma, non-serious adverse events (each reported separately), and sustained virological response. We systematically assessed risks of bias, performed Trial Sequential Analysis, and followed an eight-step procedure to assess thresholds for statistical and clinical significance. The overall quality of the evidence was evaluated using GRADE. We included a total of 138 trials randomising a total of 25,232 participants. The 138 trials assessed the effects of 51 different DAAs. Of these, 128 trials employed matching placebo in the control group. All included trials were at high risk of bias. Eighty-four trials involved DAAs on the market or under dev